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ABSTRACT Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated
that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival.
Long-term extension trials, registries and real-world studies have also shown similar treatment effects with
pirfenidone. However, for patients with IPF to obtain the maximum benefits of pirfenidone treatment, the
potential adverse events (AEs) associated with pirfenidone need to be managed. This review highlights the
well-known and established safety profile of pirfenidone based on randomised controlled clinical trials and
real-world data. Key strategies for preventing and managing the most common pirfenidone-related AEs are
described, with the goal of maximising adherence to pirfenidone with minimal AEs.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive and fatal fibrotic lung disease, with an
approximate median survival of 2–5 years from the time of diagnosis [1–4]. IPF is one of the most commonly
encountered interstitial lung diseases (ILDs), with increasing incidence and prevalence worldwide [5–7].
Pirfenidone is an oral anti-fibrotic and anti-inflammatory agent that was previously approved in Europe in
2011 for the treatment of IPF and in the USA in 2014 [8]. In the 2015 update to the American Thoracic
Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association
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treatment guidelines, pirfenidone was listed as one of only two novel agents conditionally recommended
for the treatment of IPF [9].
This review highlights the safety profile of pirfenidone based on clinical trial experience and real-world
data. Strategies for mitigating the most common gastrointestinal (GI) and skin-related adverse events
(AEs), as well as how to manage these AEs in patients with IPF based on clinical and real-world
experience with pirfenidone, are described.
Pirfenidone efficacy
Pirfenidone was evaluated in patients with IPF in three pivotal, multinational, randomised,
placebo-controlled phase III trials: CAPACITY (PIPF-004/006; NCT00287716/NCT00287729) and
ASCEND (PIPF-016; NCT01366209) [10, 11]. The phase III clinical trials assessed pirfenidone in patients
with IPF who had a forced vital capacity (FVC) of ⩾50% predicted and diffusing capacity for carbon
monoxide (DLCO) of ⩾35% pred (CAPACITY) or FVC of 50–90% pred and DLCO of ⩾30% pred
(ASCEND). Improved outcomes, including reduced lung function decline, slowed disease progression and
reduced mortality, were observed in patients treated with pirfenidone [10–13].
The benefit of continued treatment with pirfenidone despite disease progression was observed in pooled
post hoc analyses from the phase III trials, emphasising the importance of persistence with pirfenidone
treatment [14, 15].
In real-world studies of pirfenidone in patients with IPF, the effects of pirfenidone on reducing FVC
decline were consistent with findings from the clinical trials [16–19]. However, differences in baseline
characteristics and data analysis (including the availability of long-term follow-up data) may have affected
how real-world data were interpreted. Of note, the inclusion criteria for clinical trials are very stringent
and do not necessarily reflect real-world patients and practices.
Pirfenidone safety and tolerability
Pirfenidone has a well-characterised long-term safety and tolerability profile. The most commonly reported
AEs due to pirfenidone are GI- and skin-related (table 1).
TABLE 1 Clinical and real-world safety experience with pirfenidone
Clinical trial experience Real-world experience
Pooled phase III
trials# [12]
Integrated trials¶
[20]
EAP [21] PASSPORT [22]
Patients n 623 1299 1620 1009
Duration of treatment years+ 1.0 (0–2.3) 1.7 (0–9.9) 0.45 (0–0.91) 1.0 (0–2.4)
Cumulative total exposure PEY 735.7 3159.9 707.9 415
AE type TEAE TEAE ADR ADR
TEAEs or ADRs per 100 PEY§
Total 418.8 790.2 419.6 67.0
Nausea 38.6 26.0 62.1 20.4
Rash 33.3 16.2 19.3 12.7
Diarrhoea 26.0 20.1 27.6 10.6
Fatigue 21.2 16.0 52.4 17.9
Dyspepsia 16.3 9.5 16.4 4.6
Anorexia 10.2 7.1 16.8 NA
Dizziness 9.9 12.7 14.4 6.5
Gastro-oesophageal reflux disease 7.1 6.6 12.7 1.9
Decreased appetite 6.8 5.1 13.7 15.8
Decreased weight 3.4 7.3 6.6 15.6
ADR/TEAE resulting in death 2.2 18.5ƒ NA 1.4
ADR/TEAE leading to discontinuation 14.6 29.7 68.0
EAP: expanded access programme; PEY: patient-exposure years; AE: adverse event; TEAE:
treatment-emergent adverse event; ADR: adverse drug reaction; NA: not available. #: CAPACITY (004/006)
and ASCEND (016); ¶: phase III trials+RECAP+PIPF-002, including two patients in the PIPF-002 study with a
diagnosis of “pulmonary fibrosis”; +: data presented as median (range); §: one PEY is the equivalent of one
patient exposed to a study drug for 1 year, total PEY is the sum of the PEY for each patient, adjusted rate
per 100 PEY=(total number of events/total years of exposure)×100; ƒ: combined data for death and
discontinuation.
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The long-term safety of pirfenidone was evaluated in an open-label extension study of patients with IPF
who completed one of the three phase III clinical trials (RECAP, also known as PIPF-012 (NCT00662038))
[23]. The cumulative total exposure to pirfenidone in 1058 patients was 2482 patient-exposure years (PEY)
[24]. Treatment-emergent adverse events (TEAEs) were reported as rates per 100 PEY (equivalent to the
frequency at which a physician might expect these TEAEs to occur if 100 patients with IPF were followed
for 1 year). In RECAP, the most frequent TEAEs were IPF (22.0 per 100 PEY), upper respiratory infection
(21.1 per 100 PEY) and bronchitis (19.5 per 100 PEY). GI events (nausea (17.4 per 100 PEY) and
diarrhoea (14.4 per 100 PEY)), fatigue (10.1 per 100 PEY), cough (17.6 per 100 PEY) and dyspnoea (16.9
per 100 PEY) were also reported. Of note, no new safety signals were identified.
An integrated safety analysis of a large (n=1299) and well-defined cohort of patients with IPF, from an
expanded data set of five clinical trials (CAPACITY 004/006, ASCEND, RECAP and PIPF-002
(NCT00080223; a USA-only phase II, multicentre, open-label study of pirfenidone in patients with IPF
or secondary pulmonary fibrosis)), demonstrated that pirfenidone was well tolerated and reinforced the
safety profile previously characterised in the phase III trials [20]. These patients were treated for up to
9.9 years, with a cumulative total exposure to pirfenidone of 3610 PEY. Nausea (26.0 per 100 PEY),
diarrhoea (20.1 per 100 PEY), fatigue (16.0 per 100 PEY) and rash (16.2 per 100 PEY) were the most
common reported AEs in this analysis. Most AEs occurred within the first 6 months of treatment and
were generally mild to moderate in severity. The incidence of GI- and skin-related AEs declined after
the first 6-month period. Most cases were reversible or manageable by different strategies. A small
number of patients (<4%) exhibited elevations in aminotransferase levels, which tended to occur in
the first 6 months of treatment and were transient and reversible with dose modification or
discontinuation.
Earlier phase II trials of pirfenidone as combination therapy or in other ILDs have also shown a similar
safety profile. In PANORAMA, a randomised, double-blind, placebo-controlled phase II European study
that assessed the safety and tolerability of oral N-acetylcysteine (NAC) combined with pirfenidone in
patients with IPF (n=60, pirfenidone plus NAC), the addition of NAC did not significantly affect the safety
profile of pirfenidone; however, an increased incidence of photosensitivity in the pirfenidone plus NAC
versus pirfenidone plus placebo group was observed (13% versus 2%), which could not be explained by
additional analyses [25]. The most frequent other TEAEs in the pirfenidone plus NAC group were
cough (13%), nasopharyngitis (12%), diarrhoea (10%), nausea (7%), dyspnoea (7%) and bronchitis (7%).
In the group using additional NAC, a more rapid disease progression (as measured by FVC) was
observed and the authors conclude that addition of NAC to pirfenidone is unlikely to be beneficial in IPF
function [25].
In the phase II, open-label trial that assessed the safety and tolerability of pirfenidone in patients with
scleroderma-associated ILD (SSc-ILD) (LOTUSS; NCT01933334), the most commonly reported TEAEs
(nausea, headache and fatigue) were consistent with those observed in the pirfenidone phase III trials [26].
The SSc-ILD population is of particular interest for understanding how to manage pirfenidone-related
AEs, because this group may be more susceptible to certain AEs and tolerability issues, particularly GI,
skin and liver, due to the involvement of these organs in their disease [27, 28].
This safety and tolerability profile of pirfenidone observed in these large, randomised clinical trials has
been supported by extensive real-world data and post-marketing experiences. The patient populations in
these real-world studies shared similar baseline characteristics with those in the pirfenidone clinical trials.
In the expanded access programme (EAP; NCT02141087), a multicentre treatment protocol at 92 sites in
the USA that allowed patients with IPF to access pirfenidone before approval by the US Food and Drug
Administration, additional safety data were obtained, but no new safety signals were identified [21].
Adverse drug reactions (ADRs; defined by the study investigator as causally linked to drug use; 419.6 per
100 PEY) were reported in 64.9% of patients (n=1620). The most common ADRs were consistent with the
known GI- and skin-related AEs observed in the phase III clinical trials, including nausea (62.1 per
100 PEY), fatigue (52.4 per 100 PEY), diarrhoea (27.6 per 100 PEY) and rash (19.6 per 100 PEY). Similar
ADRs were the most common that led to discontinuation: nausea (6.2 per 100 PEY), fatigue (4.4 per
100 PEY) and rash (3.2 per 100 PEY).
Interim analyses from PASSPORT (n=1009), a safety registry study initiated in Europe in 2011, indicated
that the safety profile of pirfenidone in routine clinical practice was consistent with that seen in the phase
III trials, with no new or unexpected safety signals [22, 29]. The most common ADRs were nausea (20.4
per 100 PEY) and fatigue (17.9 per 100 PEY). These differences in the incidences of AEs and number of
discontinuations observed in the pirfenidone clinical trials versus the registries may be driven by the longer
duration of observation, selection/survivor bias, under-reporting in more real-world settings and/or the
higher frequency of clinical trial visits and safety assessments in the trial population.
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Prevention and management of common pirfenidone-related AEs
GI- and skin-related AEs were the most common AEs caused by pirfenidone treatment. GI events, such as
nausea, vomiting and diarrhoea, typically occur early in the course of pirfenidone treatment and decline
after the first 6 months, whereas skin-related AEs, such as rash and photosensitivity, exhibit more
variability in their time course [16, 30]. The median time to any first AE in the pooled pirfenidone phase
III trials was 15.0 days (interquartile range (IQR) 6.0–49.0 days) [31]. For pirfenidone-related AEs, the
median (IQR) time to the first GI, nausea, rash and photosensitivity AEs was 14 (5.0–40.0) days, 16.0
(7.0–62.0) days, 82 (49.0–132.0) days and 90 (48.0–149.0) days, respectively (figure 1) [31]. GI and nausea
AEs tended to occur during the peri-titration period and dermatological AEs within the first 2–3 months
of treatment.
Dose titrations
The recommended daily maintenance dose of pirfenidone is 801 mg three times per day (2403 mg·day−1)
with a 14-day titration period upon treatment initiation (table 2) [8]. However, varying the dose titration
schedule by using a slower titration may have been an effective means for mitigating the onset of
pirfenidone-related AEs. In LOTUSS, a longer titration schedule (4 weeks versus 2 weeks) was associated
with better pirfenidone tolerability (table 2) [26]. The 4-week titration schedule was tested with
pirfenidone in this specific population because patients with SSc-ILD may be more susceptible to GI-,
skin- and liver-related AEs due to the nature of their disease [27, 28]. Patients in the 2-week titration
group had more dose modifications overall compared with the 4-week titration group during the titration
period (dose reductions: 21.9% versus 3.2%, difference 18.7%, p=0.0534; dose interruptions: 12.5% versus
0%, difference 12.5%, p=0.1132) as well as more discontinuations due to a TEAE (15.6% versus 3.2%).
Patients in the 2- and 4-week groups had a similar AE profile, most commonly reporting nausea, headache
and fatigue, like patients with IPF; however, more patients experienced a severe TEAE in the 2-week
subgroup. These results suggest that titration periods of >2 weeks may be associated with a better
tolerability profile by preventing AEs and further dose modifications for patients receiving pirfenidone.
Dose modifications
Dose modifications, including reductions or interruptions, are key strategies for AE management with
pirfenidone treatment. In the phase III trials, dose reductions and interruptions occurred in 46% and 41%
of patients receiving pirfenidone, respectively, with a median duration of 28 days and 14 days, respectively
[32]. In the pirfenidone-treated population (n=623), 32.7% of patients experienced any dose reduction
with a median of 23.5 days (IQR 7–95 days) and 34.3% of patients experienced any dose interruption, with
a median of 17.0 days (IQR 8–43 days). The majority of dose reductions occurred during the first
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FIGURE 1 Kaplan–Meier analysis of time to first occurrence of a pirfenidone-related adverse event (AE) as
measured from randomisation, irrespective of treatment duration, in the pooled phase III clinical trials. GI:
gastrointestinal. #: includes all AEs of nausea; these AEs are also included in the group “GI disorders”.
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6 months of treatment; however, interruptions occurred regularly throughout the year. The median time
from start of pirfenidone to the first dose modification for common AEs was ∼95 days except for vomiting
(28 days) [32]. Although dose modifications with pirfenidone may be required to manage AEs, AEs tended
to occur early and were limited in duration, which will allow patients to maintain a high dose intensity.
TABLE 2 Alternative titration strategies with pirfenidone
Morning (breakfast) Afternoon (lunch) Evening (dinner) Total pills per day
2-week titration schedule according to prescribing information [8]
Days 1–7 1 1 1 3
Days 8–14 2 2 2 6
Days ⩾15 3 3 3 9
Modified 4-week titration schedule [26]
Days 1–14 1 1 1 3
Days 15–28 2 2 2 6
Days ⩾29 3 3 3 9
Each pill is 267 mg. Full dose of pirfenidone is 2403 mg·day−1.
TABLE 3 Summary of pirfenidone-related adverse event (AE) management strategies
Pirfenidone-related
AEs
Prevention Management
General Slower titration schedule Dose reductions
Dose interruptions
Gastrointestinal Taking pirfenidone with a substantial meal, specifically
the full dose at the end of a meal or spreading out
during a meal
Dose reductions/interruptions with a slow titration
back to full dose
Reduce the morning dose if nausea is experienced
at that time of day
Proton-pump inhibitors
Skin Continuous skin protection with clothing and
broad-spectrum SPF 50 sunscreen
Avoid use of other medications associated with
phototoxicity
With severe phototoxicity, treat with steroids or
silver sulfadiazine
Dose reductions for a rash followed by
discontinuation if the rash persists and a slow
titration back to full dose
Discontinuation if an allergic reaction to pirfenidone
occurs
Liver Perform AST, ALT and bilirubin tests before
pirfenidone initiation
Monitor at monthly intervals for the first 6 months and
then every 3 months thereafter
If AST and ALT elevations (>3× to ⩽5× ULN) occur
without symptoms or hyperbilirubinaemia, the
dose may be reduced or interrupted until values
return to normal
If AST and ALT elevations (>3× to ⩽5× ULN) are
accompanied by hyperbilirubinaemia,
permanently discontinue pirfenidone
If patients exhibit >5× ULN, permanently
discontinue pirfenidone
Important considerations
with drug–drug
interactions
For strong CYP1A2 inhibitors, such as fluvoxamine and
enoxacin, pirfenidone should be reduced to 267 mg
three times daily (801 mg·day−1)
For moderate CYP1A2 inhibitors, such as ciprofloxacin
at a dosage of 750 mg twice daily, pirfenidone should be
reduced to 534 mg three times daily (1602 mg·day−1)
SPF: sun protection factor; AST: aspartate transaminase; ALT: alanine transaminase; ULN: upper limit of normal; CYP1A2: cytochrome P450 1A2.
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Real-world studies have also assessed the use of dose modifications in AE management with pirfenidone.
An interim analysis of PASSPORT showed that the rate of discontinuations due to ADRs was lower in
patients who had a dose adjustment compared with those who did not (20% versus 33%) [22]. In the EAP,
of the patients who reached the full daily dose and then had dose modifications/interruptions (and did not
discontinue due to an ADR), almost half were able to return to the full dose by the end of the study,
suggesting that dose modifications/interruptions may be an effective strategy to allow continuation of
treatment with pirfenidone [21].
Smaller, single-centre studies have also documented the benefits of maintaining patients on pirfenidone
treatment with dose modifications. In a single-centre, retrospective, observational study of 351 patients
who were receiving pirfenidone, 75% of reported AEs were GI-related, with loss of appetite (17%) and
nausea/vomiting (15%) being most frequent, similar to what was observed in the phase III trials [10, 11, 33].
The highest number of treatment discontinuations occurred with appetite loss and nausea/vomiting
(28 and 22, respectively). These AEs were managed by dose reduction and slower dose titrations. Overall,
30% of pirfenidone patients had dose modifications and 29% discontinued permanently due to AEs. Of
note, the patients who discontinued treatment had more severe disease by baseline DLCO (<40%),
indicating that additional strategies may be required for patients who suffer from more severe lung
function impairment.
It is important to consider the impact of dose modification on pirfenidone efficacy. A post hoc analysis of
the pooled phase III pirfenidone trials assessed the impact of dose reductions and interruptions on the
annual rate of FVC decline as a function of dose intensity (>90% of the recommended maintenance dose
of 2403 mg·day−1 versus ⩽90% [32]). A dose intensity of >90% was observed in 424 out of 623
pirfenidone-treated and 559 out of 624 placebo-treated patients. The mean±SEM difference in annual rate
of FVC decline between pirfenidone and placebo over 52 weeks was 105.5±18.4 mL for a dose intensity of
>90% (p<0.0001) and 102.1±43.4 mL for ⩽90% (p=0.0191), indicating that the benefit of pirfenidone on
FVC was maintained when dose modification was needed. In addition, the dose response with regard to
the rate of FVC decline observed in the CAPACITY-004 trial supports the strategy of maintaining the full
recommended dose (2403 mg·day−1) of pirfenidone for as long as possible and, when necessary, reducing
the dose rather than discontinuing treatment. Patients who received pirfenidone 1197 mg·day−1 had more
FVC decline than patients who were receiving the full dose of 2403 mg·day−1, but less than those receiving
placebo [10].
GI-related AEs
An expert panel has recommended stepwise management strategies to prevent and mitigate GI and skin
pirfenidone-related AEs and help maintain pirfenidone at an optimal dose for long-term treatment [34].
The preferred approach to managing GI AEs is a temporary dose reduction or interruption, with a slow
titration back to the full or previously prescribed dose (table 3). The eating habits of the patient should be
considered when adjusting the pirfenidone dose. Taking pirfenidone with a substantial amount of food,
specifically the full dose at the end of a substantial meal or spreading out the three capsules during the
meal, may reduce the rate of pirfenidone absorption and mitigate the onset of GI-related AEs [35–37].
GI and skin pirfenidone-related AEs are manageable with appropriate patient support and education by
nurses and physicians. Providing patient education on the timing of these events is a proactive method to
improve pirfenidone adherence. One real-world study found that after the occurrence of a GI-related AE
within the first 8 weeks and subsequent consultation with a nurse specialist for the following 3 months,
pirfenidone adherence was improved by reinforcing necessary management techniques [16].
Skin-related AEs
One of the most effective management strategies of skin pirfenidone-related AEs is reducing sun exposure
through the use of sunscreen and clothing during pirfenidone use [30]. However, if severe phototoxicity
occurs, topical treatment with steroids or silver sulfadiazine can alleviate symptoms. The management of
skin rashes, including the appropriate diagnosis and control of allergic rashes, is also important and may
lead to pirfenidone discontinuation. Similar to GI pirfenidone-related AEs, dose reductions or
interruptions can be used (table 3).
Liver function AEs
Monitoring liver function is also important during pirfenidone treatment [8]. Elevations of aspartate
transaminase (AST) and alanine transaminase (ALT) levels to >3× the upper limit of normal (ULN)
occurred in the phase III trials (3.2%), which were managed by dose modifications or discontinuation
[12]. If AST and ALT elevations (>3× to ⩽5× ULN) occur without symptoms or hyperbilirubinaemia, the
dose may be reduced or interrupted until values return to normal. If the AST and ALT elevations (>3× to
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⩽5× ULN) are accompanied by hyperbilirubinaemia, pirfenidone should be permanently discontinued. If
patients exhibit >5× ULN, pirfenidone should be permanently discontinued. These tests should be
conducted before initiation of pirfenidone treatment and at monthly intervals for the first 6 months and
then monitored every 3 months thereafter (table 3) [8].
Fatigue
Fatigue is an important pirfenidone-related AE that affects patient quality of life, but is often hard to
distinguish from symptoms of the progressive disease [38]. In the pooled phase III trials, fatigue was
reported at a rate of 21.2 per 100 PEY [12]. A recent real-world Danish study reported the frequency of
fatigue at a higher rate than that in the phase III trials, which had an onset within a few weeks after
treatment initiation and was managed by dose modification [39].
AE management in specific patient subgroups
Elderly patients
IPF is strongly associated with age and older patients have a significantly worse prognosis with the disease
[1, 2, 40, 41]. Elderly patients with IPF also exhibit differences in their rate of decline and have been
categorised as either “fit” or “frail”; these patients face specific challenges, such as a more aggressive
disease course, lead-time bias with or without delay in diagnosis, and more severe impact of
IPF-associated comorbidities [41]. An important consideration for physicians is the number of
concomitant medications that elderly patients with IPF receive to manage the comorbidities. Thus, these
patients should be carefully monitored for drug–drug interactions, because the patients may be required to
take a large amount of oral medications at the same time, which may significantly affect pirfenidone
metabolism by inhibiting or inducing hepatic enzyme systems (cytochrome P450 1A2 (CYP1A2),
CYP3A4, P-glycoprotein) [41]. For strong CYP1A2 inhibitors such as fluvoxamine and enoxacin,
pirfenidone should be reduced to 267 mg three times daily (801 mg·day−1) [8]. For moderate CYP1A2
inhibitors, such as ciprofloxacin at a dosage of 750 mg twice daily, pirfenidone should be reduced to
534 mg three times daily (1602 mg·day−1) [8]. They should also be assessed for GI intolerance, skin
reactions and liver enzyme elevations.
A subgroup analysis of patients aged >65 years in the two CAPACITY studies showed that there was not
an increased incidence of AEs in this population [10]. However, patients aged ⩾80 years were excluded
from the pirfenidone phase III trials, indicating a need for further studies or real-world data for these
drugs in this population. More recently in the EAP study, which did not have an upper age limit, a slight
age-related increase in the proportion of patients with ⩾1 ADR was observed, with the highest percentage
in patients aged ⩾80 years. Similarly, the proportion of patients with ADRs leading to dose
modification/interruption or discontinuation also increased with increasing age: an ADR leading to dose
modification/interruption occurred in 32.7% of patients aged ⩾80 years and in 18.0% of patients aged
<65 years, while an ADR leading to discontinuation occurred in 20.9% of patients aged ⩾80 years and in
7.5% of patients aged <65 years [42]. In a pooled analysis of patients aged ⩾80 years treated with
pirfenidone from RECAP, EAP and an interim PASSPORT analysis (n=370), the safety profile was
generally consistent with the overall population from the phase III trials, with the most common ADRs
being nausea (33.5 per 100 PEY), fatigue (26.3 per 100 PEY) and diarrhoea (18.1 per 100 PEY) [42].
When patients aged ⩾80 years were assessed by body mass index, those considered normal/underweight
experienced more fatigue, decreased weight, decreased appetite and anorexia, whereas rash was observed
equally across body mass index strata. Thus, because this patient population may have a higher number of
comorbidities and concomitant medication use, physicians may need to implement more careful
management and treatment strategies.
Perioperative management and lung transplant
A Japanese phase II trial assessed the safety and efficacy of pirfenidone for the prevention of IPF acute
exacerbations in patients with lung cancer undergoing pulmonary resection (PEOPLE study) [43]. Only
one acute exacerbation was observed in 32 patients with IPF who were treated with pirfenidone and
underwent surgery.
Currently there are no established guidelines regarding pirfenidone therapy in perioperative lung
transplant [44]. Several case studies of pirfenidone use have been reported. In a single-centre, retrospective
study, 12 patients with IPF receiving pirfenidone underwent lung transplant, with all patients discharged
from the hospital without wound-healing issues or other complications [45]. Pirfenidone has been
successfully administered as a bridge to lung transplant in three patients, with no AEs reported [46].
Following lung transplant, pirfenidone was administered successfully in a woman who experienced
progressive allograft dysfunction [47]. In another single-centre, retrospective analysis at a large-volume
transplant centre, seven patients receiving pirfenidone underwent lung transplant with no serious
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post-operative AEs observed and no major drug interactions with other perioperative medications [44].
These experiences suggest that pirfenidone can be safely administered before lung transplant with good
long-term outcomes.
Patients with severe lung function impairment
Patients with severe lung function impairment (i.e. FVC <50% pred or DLCO <35% or <30% pred) were
excluded from the phase III clinical trials with pirfenidone. Therefore, information about how to manage
these patients in clinical practice cannot be obtained from these randomised clinical trials. For 54 patients
who had FVC <50% pred at baseline upon entering the open-label extension study RECAP, a higher rate
of GI AEs (nausea 37.0%, vomiting 16.7%) and a lower rate of skin AEs (rash 13.0%) was observed
compared with the 530 patients who had FVC ⩾50% pred [48]. However, in an additional analysis of 187
patients who entered RECAP with FVC <50% pred or DLCO <35% pred, their safety profiles with
pirfenidone were similar to those of patients who matched the clinical trial population [49]. In a
real-world population of patients who received pirfenidone with FVC <50% pred, a higher rate of nausea
was also observed [50].
Patients with comorbidities
Comorbidities have a significant impact on symptoms and survival associated with IPF. Cardiovascular
comorbidities and risk factors are common in IPF [51]. There are no specific warnings or precautions for
the use of pirfenidone in patients with cardiovascular comorbidities or in those receiving concomitant
anticoagulation therapy, and pharmacodynamics studies have not indicated that pirfenidone prolongs the
QTc interval [8]. Of note, the incidence of major cardiac and bleeding AEs was similar over ∼14 months
between pirfenidone and placebo groups in the pooled phase III population [52].
Future research
Various AE management strategies, including a slower dose titration for initiating treatment, taking
pirfenidone with substantial meals, spacing capsules throughout the meal, diet modification, weight-based
dosing regimens and dose reductions and interruptions, are all worthy of consideration for future clinical
studies. An important question that still remains is understanding how anti-fibrotics, including
pirfenidone, affect perioperative safety for patients with IPF who require surgery, including lung
transplant. For skin AEs, there are questions about the efficacy of sunscreen in preventing
pirfenidone-related rash. Although GI- and skin-related AEs have been commonly addressed in patients
with IPF who receive pirfenidone, there is a growing need to understand how to manage fatigue in
patients with IPF, whether as a manifestation of the underlying disease or comorbidities or as a side-effect
of pirfenidone treatment.
Summary
The safety data from pirfenidone extension studies, registries and real-world experiences are consistent
with pirfenidone’s safety profile, as observed in randomised controlled clinical trials. Similar safety profiles
have also been observed across different subgroups of interest. GI- and skin-related pirfenidone AEs have
exhibited a typical time course that can be mitigated by various prevention and management strategies.
Overall, increased vigilance during this time period and dose adjustments are key long-term approaches to
managing side-effects and maintaining adherence to pirfenidone therapy (table 3). These dose modifications
are flexible and can be optimised for patients based on the severity of observed AEs and responses to
changes in dose levels [19]. Physicians must consider the balance between AEs and efficacy in slowing lung
function decline when applying these strategies to maintain optimal adherence to pirfenidone therapy [37].
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